Table 2 Combinations of therapeutic targets (from the TTD database) that perturb the RA macrophages’ phenotypes.
From: Large-scale computational modelling of the M1 and M2 synovial macrophages in rheumatoid arthritis
Synergistic combination in the model | Targets | Target type | Associated disease(s) | Drugs with highest status | Effect of the RA macrophages' phenotypes |
|---|---|---|---|---|---|
JAK1 and JAK2 | JAK1 | Successful targets | Acquired hypomelanotic disorder, Atopic eczema, Crohn disease, Myeloproliferative neoplasm, Pancreatic cancer, ... | Baricitinib (Approved) | -Induction of the M1 macrophage apoptosis -Suppression of the M1 macrophage proliferation |
JAK2 | Successful targets | Acquired hypomelanotic disorder, Atopic eczema, Myeloproliferative neoplasm, Pancreatic cancer, Rheumatoid arthritis, ... | Baricitinib (Approved) | ||
ERK1 and Notch1 | ERK1 | Clinical trial target | Melanoma, Pancreatic cancer, Cancer, Arteries/arterioles disorder, Mature T-cell lymphoma. | BVD-523 (Phase 2) | -Induction of the M1 macrophage apoptosis -Suppression of the M1 macrophage proliferation |
Notch1 | Clinical trial target | Lymphoma, Mature T-cell lymphoma, Cancer. | LY3039478 (Phase 1/2) |
